Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

NCT05817214 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Cadonilimab
DRUG: Anlotinib
DRUG: Granulocyte-Macrophage Colony-Stimulating Factor

Sponsor

Zhongnan Hospital

Collaborators

[object Object]